The new automated external defibrillator allows emergency responders to pre-program a shock instead of pushing the “shock” button.
Medical device maker Zoll Medical is among the 1st medical device companies to sign on to the patient safety and medical device data pledge proposed by Masimo (NSDQ:MASI) founder & CEO Joe Kiani this weekend.
The pledge includes promises to open up patient data gathered by medical devices to clinicians, patients and anyone else who can help improve patient care.
ZOLL shares jumped 23.5% to $92.74 in morning trading today, after the Chelmsford, Mass.-based resuscitation device maker said it reached an agreement to merge with Asahi.
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.
Less than a month after new CEO Omar Ishrak signaled Medtronic’s (NYSE:MDT) continued interest in selling its troublesome Physio-Control resuscitation business, the company found a buy ready to put nearly half a billion dollars on the table: private equity firm Bain Capital.
A change to the way the LifeVest is reimbursed by Medicare would affect just 8 percent of Zoll Medical Corp.’s (NSDQ:ZOLL) total sales, CEO Richard Packer told a group of analysts Wednesday.
It’s been a rough end of the summer on The Street for Zoll Medical Corp. (NSDQ:ZOLL), which has seen its share price cut nearly in half over the past six weeks.
On August 1 shares of the Chelmsford, Mass.-based resuscitation company hit an all-time high of $70.82 during midday trading on Wall Street. Investors, buoyed by the company’s strong earnings results, helped push the stock price to new heights.